Document is current
Any future updates will be listed below
-
Authors
Friedrich, Matthias
Pohin, Mathilde http://orcid.org/0000-0003-2809-9498
Jackson, Matthew A.
Korsunsky, Ilya http://orcid.org/0000-0003-4848-3948
Bullers, Samuel J.
Rue-Albrecht, Kevin http://orcid.org/0000-0003-3899-3872
Christoforidou, Zoe
Sathananthan, Dharshan
Thomas, Tom
Ravindran, Rahul
Tandon, Ruchi
Peres, Raphael Sanches
Sharpe, Hannah http://orcid.org/0000-0002-1194-2429
Wei, Kevin
Watts, Gerald F. M.
Mann, Elizabeth H. http://orcid.org/0000-0001-8339-2094
Geremia, Alessandra
Attar, Moustafa
Barone, Francesca
Brenner, Michael
Buckley, Christopher D.
Coles, Mark
Frei, Andreas P. http://orcid.org/0000-0002-9996-8251
Lassen, Kara G.
Powrie, Fiona M.
McCuaig, Sarah http://orcid.org/0000-0002-2304-7739
Thomas, Lloyd
Collantes, Elena
Uhlig, Holm H. http://orcid.org/0000-0002-6111-7355
Sansom, Stephen N. http://orcid.org/0000-0003-4569-8513
Easton, Alistair http://orcid.org/0000-0001-8148-5406
Raychaudhuri, Soumya http://orcid.org/0000-0002-1901-8265
Travis, Simon P. http://orcid.org/0000-0002-2690-4361
Powrie, Fiona M. http://orcid.org/0000-0003-3312-5929
,
,
-
License Information
Text and Data Mining valid from 2021-10-21
Version of Record valid from 2021-10-21
-
More Information
Article History
Received: 6 February 2021
Accepted: 26 August 2021
First Online: 21 October 2021
Competing interests
: F.M.P. received research support from Roche and Janssen, and consulting fees from GSK, Novartis and Genentech. H.H.U. received research support or consultancy fees from Janssen, Eli Lilly, UCB Pharma, BMS/Celgene, MiroBio, Mestag and OMass. S.P.T. received research support from AbbVie, Buhlmann, Celgene, IOIBD, Janssen, Lilly, Pfizer, Takeda, UCB, Vifor and the Norman Collisson Foundation; consulting fees from AbbVie, Allergan, Αbiomics, Amgen, Arena, Asahi, Astellas, Biocare, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Buhlmann, Celgene, Chemocentryx, Cosmo, Enterome, Ferring, Giuliani SpA, GSK, Genentech, Immunocore, Immunometabolism, Indigo, Janssen, Lexicon, Lilly, Merck, MSD, Neovacs, Novartis, NovoNordisk, NPS Pharmaceuticals, Pfizer, Proximagen, Receptos, Roche, Sensyne, Shire, Sigmoid Pharma, SynDermix, Takeda, Theravance, Tillotts, Topivert, UCB, VHsquared, Vifor and Zeria; and speaker fees from AbbVie, Amgen, Biogen, Ferring, Janssen, Pfizer, Shire, Takeda and UCB (no stocks or share options). M.A.J. is an employee of MiroBio Ltd. K.G.L. and A.P.F. are employees of Roche Ltd. All other authors declare no competing interests.
